Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO.

S PizzamiglioC M CiniselliE de AzambujaD Agbor-TarhA Moreno-AspitiaT M SuterA TramaM C De SantisL De CeccoM V IorioM SilvestriG PruneriPaolo VerderioS Di Cosimo

Published in: Breast cancer research and treatment (2024)

This study provides proof of concept that circulating microRNAs tested soon after treatment start could serve as biomarkers of cardiotoxicity in a very early stage in breast cancer patients receiving anti-HER2 therapy.

Keyphrases

early stage
positive breast cancer
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
peritoneal dialysis
left ventricular
radiation therapy
mesenchymal stem cells
lymph node